A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HS-10374 in Healthy Subjects
Latest Information Update: 18 Sep 2023
At a glance
- Drugs HS-10374 (Primary)
- Indications Psoriasis
- Focus Adverse reactions; First in man
- Sponsors Jiangsu Hansoh Pharmaceutical
Most Recent Events
- 18 Sep 2023 New trial record